11 To 14 Amino Acid Residues In Defined Sequence Patents (Class 530/327)
-
Publication number: 20140243256Abstract: The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15).Type: ApplicationFiled: March 14, 2013Publication date: August 28, 2014Applicant: The Administrators of the Tulane Educational FundInventors: Jennifer S. SPENCE, Robert F. GARRY
-
Publication number: 20140242068Abstract: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.Type: ApplicationFiled: August 10, 2012Publication date: August 28, 2014Applicant: EMORY UNIVERSITYInventors: Charles A. Parkos, Dominique A. Weber
-
Patent number: 8815214Abstract: Provided is a family of intramolecularly quenched imaging agents for use in both in vivo and in vitro imaging that contain at least one enzymatically cleavable oligopeptide and two fluorophores or a fluorophore and a quencher. When subjected to proteolytic cleavage, at least one fluorophore is unquenched and becomes capable of producing a fluorescent signal upon excitation with light of an appropriate wavelength. Also provided are in vivo and in vitro imaging methods using such imaging agents.Type: GrantFiled: January 17, 2009Date of Patent: August 26, 2014Assignee: VisEn Medical, Inc.Inventors: Milind Rajopadhye, Kevin Groves, Dorin V. Preda
-
Patent number: 8815807Abstract: Compositions and kits are provided having a peptide having an amino acid sequence that binds to eukaryotic cells and effects differentiation and support growth of the cells. Peptide-scaffold compositions containing at least one peptide or combinations of peptides are therapeutic agents for stimulating and promoting osteogenic activity and osteoinduction activity for cells. The scaffold is for example apatite, natural cancellous bone, demineralized natural cancellous bone, collagen, calcium phosphate, or hydroxyapatite.Type: GrantFiled: December 2, 2011Date of Patent: August 26, 2014Assignee: President and Fellows of Harvard CollegeInventors: Shigemi Nagai, Masazumi Nagai, Mindy Sungmin Gil
-
Patent number: 8816047Abstract: Embodiments relate to proislet peptides, preferably HIP, that exhibit increased stability and efficacy, and methods of using the same to treating a pathology associated with impaired pancreatic function, including type 1 and type 2 diabetes and symptoms thereof.Type: GrantFiled: August 29, 2008Date of Patent: August 26, 2014Assignee: Cure DM Group Holdings, LLCInventors: Claresa S. Levetan, Victor M. Garsky, Loraine V. Upham
-
Patent number: 8816048Abstract: The invention is directed to peptides. Specifically, the invention is directed to peptides which bind skin and do not bind hair. Alternatively, the invention is drawn to peptides which bind hair and do not bind skin.Type: GrantFiled: August 28, 2013Date of Patent: August 26, 2014Assignee: Danisco US Inc.Inventors: Giselle G. Janssen, Christopher J. Murray, Deborah S. Winetzky
-
Patent number: 8815794Abstract: In its various embodiments, the invention provides myelin basic proteins and fragments of that interfere with the fibril lization of peptides implicated in the amyloidoses, especially the amyloid-beta peptide associated with Alzheimer's disease (“AD”) and cerebral amyloid angiopathy (“CAA”). Some embodiments provide methods of identifying additional interfering fragments. Others provide methods of identifying substances that modulate the interference. Further embodiments provide methods of preventing amyloidoses, especially AD and CAA by administering myelin basic proteins or fragments thereof.Type: GrantFiled: August 28, 2009Date of Patent: August 26, 2014Assignee: The Research Foundation for the State University of New YorkInventor: William E. Van Nostrand
-
Publication number: 20140234334Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.Type: ApplicationFiled: July 9, 2013Publication date: August 21, 2014Applicant: AMGEN INC.Inventors: Hosung MIN, Hailing HSU, Fei XIONG
-
Publication number: 20140235822Abstract: The present invention provides a method for producing a peptide, characterized in that it comprises converting an —SH group of a peptide comprising an amino acid residue having the —SH group to an —OH group, wherein said method comprises the following steps (a) to (c): (a) allowing an —SH group in a peptide to react with a methylating agent to convert the —SH group to an -SMe group; (b) allowing the -SMe group obtained in the step (a) to react with a cyanizing agent to produce a reaction intermediate; and (c) converting the reaction intermediate obtained in the step (b) to a peptide comprising an amino acid residue having an —OH group under more basic conditions than the conditions in the step (b).Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicant: Glytech, Inc.Inventors: Yasuhiro Kajihara, Izumi Sakamoto, Yuri Nambu, Kazuhiro Fukae, Hiroaki Asai
-
Publication number: 20140235820Abstract: The invention provides methods and compositions for modulating the Wnt signaling pathway, in particular by interfering with binding of Dkk1 or SOST with LRP5 and/or LRP6.Type: ApplicationFiled: April 29, 2014Publication date: August 21, 2014Applicant: GENENTECH, INC.Inventors: Eric Bourhis, Andrea Cochran, Yingnan Zhang
-
Patent number: 8809275Abstract: Provided herein are peptoids capable of inhibiting or reversing amyloid ? (A?) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least two monomers with a side-chain having an arylalkyl group having the same chirality positioned such that the side-chains are on the same side of the peptoid. Also provided are methods of using the peptoids to inhibit or reverse aggregation of A? and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD.Type: GrantFiled: October 19, 2012Date of Patent: August 19, 2014Assignees: The Board of Trustees of the University of Arkansas, University of South CarolinaInventors: Shannon Servoss, Melissa Moss
-
Patent number: 8809279Abstract: Peptide compounds of the following general formula (I): R1-(AA)n-X1-X2-X3-Lys-Lys-Gln-Lys-Trp-X4-(AA)p-R2 are disclosed herein. The peptide compounds can be used as Telomeric repeat-binding factor 2 (TRF2) protein-modulating compounds and have a preventive action on deoxyribonucleic acid (DNA) double-strand breaks. In addition, cosmetic compositions that include at least one peptide of general formula (I) in a physiologically acceptable medium are disclosed along with methods for preventing and/or treating cutaneous signs of aging and photoaging.Type: GrantFiled: April 27, 2012Date of Patent: August 19, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20140228293Abstract: The present invention provides parathyroid hormone and/or parathyroid hormone-related protein analogs, compositions thereof and methods thereto.Type: ApplicationFiled: March 1, 2012Publication date: August 14, 2014Applicants: THE GENERAL HOSPITAL CORPORATION, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Samuel J. Danishefsky, Shiying Shang, Zhongping Tan, Suwei Dong, Jianfeng Li, Thomas Gardella
-
Publication number: 20140227279Abstract: Compositions and methods for the treatment of autoimmune and inflammatory diseases are disclosed.Type: ApplicationFiled: August 9, 2012Publication date: August 14, 2014Applicant: Lankenau Institute for Medical ResearchInventors: Lisa Laury-Kleintop, Laura Mandik-Nayak, George C. Prendergast, James Duhadaway
-
Publication number: 20140228277Abstract: The invention provides peptide inhibitors of BACE1 that bind to the active site in a noncanonical fashion, and methods of use thereof.Type: ApplicationFiled: October 12, 2012Publication date: August 14, 2014Inventors: Robert A. Lazarus, Yingnan Zhang, Weiru Wang
-
Patent number: 8801955Abstract: Disclosed are water-soluble nanoparticles. The water-soluble nanoparticles are each surrounded by a multifunctional group ligand including an adhesive region, a cross linking region, and a reactive region. In the water-soluble nanoparticles, the cross-linking region of the multifunctional group ligand is cross-linked with another cross-linking region of a neighboring multifunctional group ligand.Type: GrantFiled: July 16, 2012Date of Patent: August 12, 2014Assignee: Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Jin-Woo Cheon, Young-Wook Jun, Jin-Sil Choi
-
Patent number: 8802635Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: GrantFiled: August 9, 2013Date of Patent: August 12, 2014Assignees: Oneday—Biotech And Pharma Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Patent number: 8802817Abstract: The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.Type: GrantFiled: November 20, 2012Date of Patent: August 12, 2014Assignee: BMR Solutions Ltd.Inventor: Azim Turdiev
-
Publication number: 20140219981Abstract: The present invention relates in general to the field of tissue engineering and more specifically to amphiphilic peptides and peptide matrices thereof useful in vitro and in situ biomineralization and inducing bone repair. The present invention provides peptides, which are useful in hydrogels and other pharmaceutical compositions, and methods and kits of use for bone repair and promotion of biomineralization. Certain hydrogels according to the invention comprise cells within or adhered to the peptide matrix.Type: ApplicationFiled: January 14, 2014Publication date: August 7, 2014Applicant: Ben-Gurion University of the Negev Research and Development AuthorityInventor: Hanna RAPAPORT
-
Publication number: 20140220117Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.Type: ApplicationFiled: September 12, 2012Publication date: August 7, 2014Applicant: IMMUNOTOPE, INC.Inventor: Ramila Philip
-
Publication number: 20140221273Abstract: The present disclosure provides antimicrobial peptides, and compositions comprising same. The present disclosure further provides methods of inhibiting microbial growth.Type: ApplicationFiled: April 16, 2012Publication date: August 7, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Suzanne M.J. Fleiszig, David J. Evans, Kwai Ping Tam, James J. Mun
-
Publication number: 20140220074Abstract: Peptides including an amino acid sequence of a fragment of mammalian Toll-like receptor-4 (TLR-4), analogs and derivatives thereof, and pharmaceutical compositions including these peptides. Methods for modulating a TLR-4 mediated immune response, particularly stimulating TLR-4 mediated immune response, thereby treating infectious diseases and cancer.Type: ApplicationFiled: April 10, 2014Publication date: August 7, 2014Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yechiel Shai, Yosef Rosenfeld, Neta Sal-Man
-
Publication number: 20140223588Abstract: The application relates to a polypeptide, the amino acid sequence of which is the sequence of a sub-fragment of the C-terminal thioester-cleaved fragment of human alpha-2-macroglobulin (A2M), wherein the molecular weight of said polypeptide is of 36 to 44 kDa, and wherein the first N-terminal amino acid of said polypeptide is an amino acid, which, in the full length sequence of said human A2M, is at a position 1,098 or 1,085 or 1,084 or 1,083, and the last C-terminal amino acid of said polypeptide is an amino acid, which, in the full length sequence of said human A2M, is one of the last twenty C-terminal amino acids. This polypeptide is differently abundant depending on the stage of liver fibrosis. The application also relates to means deriving therefrom and to the application thereof, notably in the field of hepatitis.Type: ApplicationFiled: July 27, 2011Publication date: August 7, 2014Applicant: BIO-RAD INNOVATIONSInventors: Isabelle Catherine Batxelli, Bénédicte Watelet
-
Publication number: 20140221610Abstract: Compositions comprising a protein or isolated peptide, and methods using the same for preventing, dispersing or detaching a biofilm, are disclosed.Type: ApplicationFiled: May 31, 2012Publication date: August 7, 2014Inventor: Amir Zlotkin
-
Patent number: 8796201Abstract: Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.Type: GrantFiled: November 4, 2011Date of Patent: August 5, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Lu Shan, Michael Bethune, Chaitan Khosla, Jonathan Gass, Gail G. Pyle, Gary M. Gray, Indu Isaacs, Gregg Strohmeier
-
Patent number: 8796223Abstract: The present invention provides methods to prevent photoreceptor death. In particular, the present invention provides peptides which prevent FAS-mediated photoreceptor apoptosis.Type: GrantFiled: January 8, 2013Date of Patent: August 5, 2014Assignee: The Regents of The University of MichiganInventor: David Noam Zacks
-
Patent number: 8796227Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.Type: GrantFiled: January 28, 2013Date of Patent: August 5, 2014Assignee: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Orly Eizenberg, Dalit Vaizel-Ohayon
-
Patent number: 8796183Abstract: A method of screening for template-fixed ?-hairpin mimetics and libraries including a plurality of these mimetics is provided. The template-fixed ?-hairpin mimetics are of the following general formula: R1-Cys-Z-Cys-R2??I wherein the two cysteine residues are bridged by a disulfide bond, thereby forming a cyclic peptide; R1 and R2 are di- or tripeptide moieties of certain types, as defined herein; and Z is a chain of n amino acid residues with n being an integer from 4 to 20 and with each of these n amino acid residues being, independently, derived from any naturally occurring L-?-amino acid.Type: GrantFiled: August 2, 2011Date of Patent: August 5, 2014Assignees: Polyphor Ltd., Universität ZürichInventors: Jan Wim Vrijbloed, Daniel Obrecht, Sergio Locurio, Frank Otto Gombert, Christian Ludin, Françoise Jung
-
Publication number: 20140213759Abstract: A process for extraction of a peptide from a reaction mixture resulting from a peptide coupling reaction, the reaction mixture containing the peptide and a polar aprotic solvent selected from the group consisting of N,N-dimethylformamide, N,N-dimethylacetamide and N-methyl-2-pyrrolidone, whereby the process includes a step a) and a step b): step a) including the addition of a component a1) and a component a2), whereby component a1) is 2-methyltetrahydrofuran and component a2) is water, to the reaction mixture, so that a biphasic system with an organic layer and an aqueous layer is obtained; step b) including the subsequent separation of the organic layer containing the peptide from the aqueous layer. In an embodiment, a combination of 2-methyltetrahydrofuran and an organic solvent 1 selected from the group consisting of n-heptane, toluene, ethylacetate, isopropylacetate, acetonitrile and tetrahydrofuran is used for the process for extraction.Type: ApplicationFiled: June 14, 2012Publication date: July 31, 2014Applicants: LONZA BRAINE S.A., LONZA LTDInventors: Didier Monnaie, Luciano Forni, Mathieu Giraud
-
Publication number: 20140212945Abstract: Disclosed are RNA targeting compounds, methods for using the subject RNA targeting compounds to treat myotonic dystrophy and other diseases are also disclosed.Type: ApplicationFiled: November 6, 2013Publication date: July 31, 2014Applicant: The Research Foundation for the State University of New YorkInventor: Matthew David Disney
-
Publication number: 20140213531Abstract: Template-fixed ?-hairpin peptidomimetics of the general formulae wherein Z is a chain of 11 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or Pro(4NHCOPhe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to inhibit proteases, in particular serine proteases, especially Cathepsin G or Elastase or Tryptase. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: December 9, 2013Publication date: July 31, 2014Applicants: Universitat Zurich, Polyphor Ltd.Inventors: Steven J. Demarco, Kerstin Moehle, Heiko Henze, Odile Sellier, Francoise Jung, Frank Gombert, Daniel Obrecht, Christian Ludin
-
Publication number: 20140213663Abstract: The objective to be solved by the present invention is to provide a novel ice crystallization inhibitor which is industrially useful, which can be efficiently and stably produced in a safe process suitable for a food production without difficulty and which has excellent functions and properties. Also, the objective of the present invention is to provide an antibody which specifically reacts with the ice crystallization inhibitor, and a composition, a food, a biological sample protectant and a cosmetic which contain the ice crystallization inhibitor. Furthermore, the objective of the present invention is to provide a peptide which gives an indication of a protein having an ice crystallization inhibitory activity. The ice crystallization inhibitor according to the present invention is characterized in comprising a seed protein derived from a plant belonging to genus Vigna in Leguminosae, an allied species thereof or an improved species thereof.Type: ApplicationFiled: March 2, 2012Publication date: July 31, 2014Inventors: Hidehisa Kawahara, Hideaki Kegasa, Naoki Arai
-
Publication number: 20140213505Abstract: Provided herein are peptide inhibitors of the interaction between End Binding Protein 3 (EB3) and Inositol 1,4,5-Trisphosphate Receptor Type 3 (IP3R3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.Type: ApplicationFiled: March 31, 2014Publication date: July 31, 2014Inventors: Yulia A. Komarova, Uzma Saqib, Stephen M. Vogel, Asrar B. Malik
-
Publication number: 20140212888Abstract: A method has been developed to efficiently proliferate and culture a CTL specific to WT1 peptides under limiting dilution conditions. Utilizing this method, CTLs capable of recognizing both a state where a wildtype WT1 specific peptide is presented by HLA-A*24:02 and a state where a mutant WT1 specific peptide is presented by HLA-A*24:02 have been successfully obtained.Type: ApplicationFiled: August 28, 2013Publication date: July 31, 2014Applicant: Medical & Biological Laboratories Co., Ltd.Inventors: Kazue WATANABE, Shingo TOJI
-
Patent number: 8791233Abstract: The present invention provides maspin-related compositions and methods of use thereof. In particular, the present invention provides maspin-related compositions, and methods or use thereof, for the promotion of cell adhesion.Type: GrantFiled: May 23, 2012Date of Patent: July 29, 2014Assignee: Northwestern UniversityInventor: Ming Zhang
-
Patent number: 8791234Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: GrantFiled: October 14, 2011Date of Patent: July 29, 2014Assignee: Rutgers, The State University of New JerseyInventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Patent number: 8791062Abstract: The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.Type: GrantFiled: July 26, 2013Date of Patent: July 29, 2014Assignee: The Regents of the University of CaliforniaInventors: Tracy Hsu, Samir M. Mitragotri
-
Publication number: 20140206839Abstract: The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.Type: ApplicationFiled: March 31, 2014Publication date: July 24, 2014Applicant: Allergan, Inc.Inventors: Gregory H. Altman, Rebecca L. Horan, Adam L. Collette, Jingsong Chen, Dennis Van Epps
-
Publication number: 20140206838Abstract: Peptide nucleic acids containing thymidine and 2-aminopyridine (M) nucleobases formed stable and sequence selective triple helices with double stranded RNA at physiologically relevant conditions. The M-modified PNA displayed unique RNA selectivity by having two orders of magnitude higher affinity for the double stranded RNAs than for the same DNA sequences. Preliminary results suggested that nucleobase-modified PNA could bind and recognize double helical precursors of microRNAs.Type: ApplicationFiled: October 29, 2013Publication date: July 24, 2014Applicant: The Research Foundation for The State University of New YorkInventors: Eriks Rozners, Thomas Zengeya
-
Publication number: 20140205621Abstract: A new pantropic canine coronavirus (CCoV) strain, having reduced pathogenicity, and capable of eliciting an immune response, is described.Type: ApplicationFiled: June 26, 2012Publication date: July 24, 2014Inventors: Nicola Decaro, Vito Martella, Gabriella Elia, Canio Buonavoglia
-
Patent number: 8784830Abstract: In order to provide an effective vaccine against infection with Propionibacterium acnes, the present invention provides a peptide which is a peptide consisting of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived from the specific amino acid sequence by deletion, substitution, insertion, or addition of one or more amino acids, the peptide suppressing, by immune response, inflammation caused by infection with Propionibacterium acnes.Type: GrantFiled: May 23, 2011Date of Patent: July 22, 2014Inventors: Kenichiro Hasumi, Mikio Kuraya
-
Publication number: 20140199318Abstract: The invention relates to means for detecting, binding, removing and/or neutralising agonistic antibodies associated with dementia, preferably Alzheimer's disease or vascular dementia.Type: ApplicationFiled: July 13, 2012Publication date: July 17, 2014Applicants: MAX-DEL-BRUCK-CENTRUM FUR MOLEKULARE MEDIZIN, E.R.D.E.-AAK-DIAGNOSTIK GMBHInventors: Marion Bimmler, Peter Karczewski, Petra Hempel
-
Publication number: 20140199333Abstract: The present disclosure provides human Aquaporin 4 (AQP4) peptides and peptides having homology to human Aquaporin 4 (AQP4) peptides. Also provided herein are methods for using human AQP4 peptides and peptides homologous to human AQP4 peptides for diagnosing and/or treating Neuromyelitis Optica.Type: ApplicationFiled: December 10, 2013Publication date: July 17, 2014Applicant: The Regents of the University of CaliforniaInventors: Scott S. Zamvil, Michel Varrin-Doyer, Bruce Anthony Campbell Cree
-
Publication number: 20140199682Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing agents against influenza A viruses, and to the neutralizing agents produced. In particular, the invention concerns neutralizing agents against various influenza A virus subtypes, and methods and means for making such agents.Type: ApplicationFiled: November 17, 2011Publication date: July 17, 2014Applicant: SEA LANE BIOTECHNOLOGIES, LLCInventors: Lawrence Horowitz, Ramesh R. Bhatt, Arun K. Kashyap
-
Publication number: 20140199762Abstract: A peptide comprising the amino acid sequence RMFPNAPYL or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence CMTWNQMNL or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence HLMPFPGPLL or a portion or variant thereof provided that the peptide is not intact human gata-1 polypeptide, and polynucleotides encoding these peptides. The peptides and polynucleotides are useful as cancer vaccines.Type: ApplicationFiled: August 14, 2013Publication date: July 17, 2014Applicant: Ganymed Pharmaceuticals AGInventors: Hans Josef STAUSS, Liquan GAO
-
Patent number: 8778891Abstract: Peptides activating dermatopontin in the skin and cosmetic compositions including such peptide, in a physiologically suitable medium, are described. Methods of treating the cutaneous signs of aging and photoaging, and in particular wrinkles, sagging, and loss of volume and elasticity of the skin are also described.Type: GrantFiled: November 7, 2011Date of Patent: July 15, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8778357Abstract: The present invention provides a method for generating negative-strand, segmented RNA viruses using linear expression constructs in the presence of helper virus.Type: GrantFiled: December 3, 2009Date of Patent: July 15, 2014Assignee: Baxter Healthcare SAInventors: Thomas Muster, Andrej Egorov, Markus Wolschek
-
Patent number: 8779091Abstract: A selective targeting method is disclosed comprising contacting a library of ligands, particularly a peptide library, with an anti-target to allow the ligands to bind to the anti-target; separating the non-binding ligands from the anti-target bound ligands, contacting the non-binding anti-target ligands with a target allowing the unbound ligands to bind with the target to form a target-bound ligand complex; separating the target-bound ligand complex from ligands which do not bind to the target, and identifying the target-bound ligands on the target-bound ligand complex wherein the target-bound ligands have a KD in the range of about 10?7 to 10?10 M. Additionally claimed are the ligands identified according to the method.Type: GrantFiled: October 23, 2012Date of Patent: July 15, 2014Assignee: Danisco US Inc.Inventors: Christopher J. Murray, Pilar Tijerina, David A. Estell, Yiyou Chen
-
Patent number: 8779090Abstract: Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described.Type: GrantFiled: February 26, 2008Date of Patent: July 15, 2014Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Daniel Zimmer, Angelika Fretzen, Mark Currie, G. Todd Milne
-
Patent number: 8778886Abstract: A peptide-POD with ability to penetrate and deliver fluorophores, siRNA, DNA and quantum dots to cells in culture and retinal and ocular tissues in vivo is provided herein. POD couples to adenovirus vectors, enhancing tropism for certain cells, potentially providing a safer and more efficacious method to deliver molecules to ocular and other tissues in vivo. POD constructs are therapeutic delivery vehicles for treating cells and tissues, including ocular cells and tissues suffering from retinal degeneration.Type: GrantFiled: February 26, 2010Date of Patent: July 15, 2014Assignee: Tufts UniversityInventors: Rajendra Kumar-Singh, Siobhan M. Cashman, Sarah Parker Read